Literature DB >> 6083417

Comparison of the antileukemic activity of 5-AZA-2'-deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia.

R L Momparler, L F Momparler, J Samson.   

Abstract

The antineoplastic activity and effect on DNA synthesis and DNA methylation of 5-aza-2'-deoxycytidine (5-AZA-CdR), 1-beta-D-arabinofuranosylcytosine (ARA-C), and 5-azacytidine (5-AZA-CR) on L1210 leukemic cells were compared. At equimolar concentrations 5-AZA-CdR produced greater growth inhibition and more cytotoxicity against the L1210 cells than either ARA-C or 5-AZA-CR. ARA-C, but not 5-AZA-CdR or 5-AZA-CR, produced a potent inhibition of DNA synthesis in the L1210 cells. 5-AZA-CdR and 5-AZA-CR, but not ARA-C, inhibited DNA methylation with 5-AZA-CdR being a more effective inhibitor than 5-AZA-CR. At maximum tolerated dose, 5-AZA-CdR produced a much greater increase in life span of mice with L1210 leukemia than ARA-C or 5-AZA-CR. These in vitro and in vivo studies indicate that 5-AZA-CdR is a more potent antineoplastic agent against L1210 leukemic cells than either ARA-C or 5-AZA-CR.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6083417     DOI: 10.1016/0145-2126(84)90059-6

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  26 in total

1.  Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase.

Authors:  J Laliberté; V E Marquez; R L Momparler
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  5-azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia.

Authors:  May Kung Sutherland; Changpu Yu; Martha Anderson; Weiping Zeng; Nico van Rooijen; Eric L Sievers; Iqbal S Grewal; Che-Leung Law
Journal:  MAbs       Date:  2010-07-01       Impact factor: 5.857

Review 3.  Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2016-05       Impact factor: 9.546

4.  A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines.

Authors:  Paul W Hollenbach; Aaron N Nguyen; Helen Brady; Michelle Williams; Yuhong Ning; Normand Richard; Leslie Krushel; Sharon L Aukerman; Carla Heise; Kyle J MacBeth
Journal:  PLoS One       Date:  2010-02-02       Impact factor: 3.240

5.  DNA-dependent protein kinase (DNA-PK)-deficient human glioblastoma cells are preferentially sensitized by Zebularine.

Authors:  Jarah A Meador; Yanrong Su; Jean-Luc Ravanat; Adayabalam S Balajee
Journal:  Carcinogenesis       Date:  2009-11-23       Impact factor: 4.944

6.  Mechanism of Hb F stimulation by S-stage compounds. In vitro studies with bone marrow cells exposed to 5-azacytidine, Ara-C, or hydroxyurea.

Authors:  R Galanello; G Stamatoyannopoulos; T Papayannopoulou
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

Review 7.  Azacitidine: a review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2009       Impact factor: 9.546

8.  Chemotherapy of L1210 and L1210/ARA-C leukemia with 5-aza-2'-deoxycytidine and 3-deazauridine.

Authors:  R L Momparler; L F Momparler
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

9.  Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy.

Authors:  Metin Karahoca; Richard L Momparler
Journal:  Clin Epigenetics       Date:  2013-02-01       Impact factor: 6.551

Review 10.  Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2012-05-28       Impact factor: 11.431

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.